安进和Kyowa Kirin公布rocatinlimab三期Ascend长期扩展研究顶线结果,针对中重度特应性皮炎成人患者

美股速递
Sep 09, 2025

安进和Kyowa Kirin近日联合宣布,针对中重度特应性皮炎成人患者开展的rocatinlimab三期临床试验Ascend长期扩展研究已获得顶线结果。

该项长期扩展研究旨在评估rocatinlimab在成人中重度特应性皮炎患者中的长期安全性和有效性。此次公布的顶线结果将为该药物的进一步开发提供重要数据支持。

特应性皮炎是一种慢性炎症性皮肤疾病,对患者的生活质量造成显著影响。rocatinlimab作为一种创新性治疗药物,在前期研究中已显示出治疗潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10